0
Obstructive Lung Diseases: COPD Pharmacotherapy |

Efficacy and Safety of Long-Term Nebulized Budesonide Inhalation in Elderly COPD Patients FREE TO VIEW

Shilei Cui, MD; Huili Zhu, MD
Author and Funding Information

Department of Respiratory Disease, Huadong Hospital, Fudan University, Shanghai, China


Copyright 2016, American College of Chest Physicians. All Rights Reserved.


Chest. 2016;149(4_S):A391. doi:10.1016/j.chest.2016.02.406
Text Size: A A A
Published online

SESSION TITLE: COPD Pharmacotherapy

SESSION TYPE: Original Investigation Poster

PRESENTED ON: Saturday, April 16, 2016 at 11:45 AM - 12:45 PM

PURPOSE: To evaluate the clinical efficacy and safety of long term inhalation of nebulized budesonide in elderly COPD patients.

METHODS: 25 elderly COPD patients of stable stage were randomly allocated in 2 treatment groups (group A: budesonide 1mg bid; group B: budesonide 2mg bid) separately. The duration of the study period was 1 year. 15 healthy old men were recruited as normal control. Forced expiratory volume in 1 second (FEV1), blood gas analysis, COPD-assessment test (CAT), glycometabolism and bone metabolism markers were checked before and after treatment.

RESULTS: In patients of group B, PaCO2 and FEV1 were significantly improved compared with baseline (P < 0.01, P < 0.05) after 1 year treatment. CAT scores markedly improved after 6 months treatment in two groups of COPD patients (P < 0.05, P < 0.01). CAT score was further improved in group B after 12 months therapy compared with 6 month therapy (P < 0.05). The ratio of CAT improvement after 6 months and 12 months were higher in group B compared with group A (P < 0.05, P < 0.01). There was no significant difference in the percentage of annual rates in acute exacerbations between two treatment groups. Compared with the normal control, no evidence showed bad effect of glycometabolism and bone metabolism in COPD patients. The incidence of pneumonia was similar in two treatment groups.

CONCLUSIONS: 1 year of nebulized budesonide could improve the lung function and clinical symptoms in elderly patients with moderate to severe COPD, without adverse effect on glycometabolism and bone metabolism. No significant increase was discovered in the incidence of pneumonia after 1 year treatment.

CLINICAL IMPLICATIONS: Nebulized budesonide is a safe and effective treatment for elderly patients with moderate to severe COPD.

DISCLOSURE: The following authors have nothing to disclose: Shilei Cui, Huili Zhu

No Product/Research Disclosure Information


Figures

Tables

References

NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).

Some tools below are only available to our subscribers or users with an online account.

Related Content

Customize your page view by dragging & repositioning the boxes below.

Find Similar Articles
CHEST Journal Articles
PubMed Articles
  • CHEST Journal
    Print ISSN: 0012-3692
    Online ISSN: 1931-3543